The SELECT Trial Enrolled 17,604 Non-Diabetic Obese Patients and Found That Semaglutide 2.4mg Reduced Major Adverse Cardiovascular Events by 20% Over 3.3 Years — a Result That Extends the GLP-1 Cardiovascular Benefit Class Effect Beyond Type 2 Diabetes and Points to Cardioprotective Mechanisms That Operate Independently of Blood Glucose Control
Quick Answer
In the SELECT trial (17,604 non-diabetic obese patients, NEJM 2023), semaglutide 2.4 mg cut major adverse cardiovascular events (MACE) by 20% over 3.3 years — the first proof of cardiovascular benefit in non-diabetics.
- •SELECT: −20% MACE in non-diabetic obese patients
- •LEADER (liraglutide): −13% MACE in type 2 diabetes
- •SUSTAIN-6: −26% MACE
- •GLP-1 receptors exist directly in the myocardium
Updated: June 2026GLP-1 cardiovascular · GLP-1 heart disease · GLP-1 heart attack · GLP-1 stroke · GLP-1 cardiovascular outcomes · semaglutide cardiovascular · semaglutide heart disease · semaglutide MACE · semaglutide cardiovascular outcomes · ozempic heart · wegovy heart · ozempic cardiovascular · wegovy cardiovascular · SELECT trial · SELECT trial semaglutide · SELECT trial results · SELECT trial MACE · SELECT trial Lincoff · Lincoff 2023 NEJM · semaglutide SELECT trial · STEP trials cardiovascular · GLP-1 MACE · MACE major adverse cardiovascular events · GLP-1 cardiovascular benefit · liraglutide cardiovascular · LEADER trial · LEADER trial results · LEADER trial liraglutide · LEADER trial MACE · Marso 2016 LEADER · liraglutide heart · liraglutide MACE · Victoza heart · semaglutide SUSTAIN-6 · SUSTAIN-6 cardiovascular · Marso 2016 SUSTAIN · dulaglutide REWIND · REWIND trial cardiovascular · exenatide EXSCEL · PIONEER-6 semaglutide oral cardiovascular · GLP-1 class effect cardiovascular · GLP-1 receptor heart · GLP-1 receptor myocardium · GLP-1 receptor cardiomyocyte · GLP-1 direct cardiac effect · GLP-1 weight independent cardiovascular · GLP-1 beyond weight loss heart · GLP-1 mechanism cardiovascular · GLP-1 anti-inflammatory cardiovascular · GLP-1 adipose inflammation cardiovascular · GLP-1 visceral fat cardiovascular · GLP-1 blood pressure cardiovascular · GLP-1 LDL cardiovascular · GLP-1 triglycerides cardiovascular · GLP-1 plaque cardiovascular · GLP-1 atherosclerosis · GLP-1 inflammation CRP · GLP-1 high sensitivity CRP · semaglutide CRP inflammation · GLP-1 endothelial function · GLP-1 vascular inflammation · GLP-1 NF-kB · GLP-1 cAMP cardioprotection · GLP-1 ischemic preconditioning · GLP-1 cardiac ischemia · GLP-1 reperfusion injury · GLP-1 heart failure · GLP-1 HFpEF · GLP-1 heart failure preserved ejection fraction · STEP-HFpEF trial · semaglutide HFpEF · heart failure obesity · obesity heart failure · GLP-1 kidney cardiovascular · FLOW trial GLP-1 · FLOW trial semaglutide · semaglutide kidney outcomes · GLP-1 renal outcomes · GLP-1 CKD · GLP-1 ASCVD · atherosclerotic cardiovascular disease GLP-1 · GLP-1 established cardiovascular disease · GLP-1 secondary prevention · GLP-1 primary prevention cardiovascular · MACE non-diabetic · semaglutide non-diabetic heart · cardiovascular weight loss drugs · obesity cardiovascular disease · adipose tissue inflammation cardiovascular · visceral fat heart disease · insulin resistance cardiovascular · metabolic syndrome cardiovascular
The cardiovascular story of GLP-1 receptor agonists is one of medicine's more remarkable reversals. When the drug class was introduced for type 2 diabetes management, regulators required cardiovascular safety trials — not cardiovascular benefit trials. The FDA's 2008 guidance followed rosiglitazone's cardiovascular harm, and the mandate was simply to prove GLP-1 drugs did not increase heart attack and stroke risk. What emerged from the subsequent decade of trials was the opposite: a consistent, statistically significant reduction in major adverse cardiovascular events (MACE — defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) across multiple GLP-1 drugs, in multiple patient populations.
The critical question was whether the cardiovascular benefit derived from glycemic control, weight loss, or something intrinsic to GLP-1 receptor activation in cardiovascular tissue. The SELECT trial (Lincoff et al. 2023, NEJM) answered this definitively by enrolling patients who were obese but not diabetic — eliminating glucose control as a confounding variable. The 20% MACE reduction in SELECT, achieved in a population with no T2D, established that GLP-1 cardiovascular benefit extends beyond its glucose-lowering mechanism and likely involves direct receptor-mediated effects on the cardiovascular system.
−20%
SELECT trial MACE reduction — SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity): Lincoff et al. 2023, NEJM; N=17,604 adults; inclusion criteria: age ≥45, BMI ≥27, established atherosclerotic cardiovascular disease (prior MI, stroke, or peripheral artery disease); CRITICAL: no type 2 diabetes — this was the defining feature of SELECT; randomized to semaglutide 2.4mg/week (Wegovy dose) or placebo; mean follow-up: 3.3 years; primary endpoint: first MACE event (cardiovascular death + non-fatal MI + non-fatal stroke); result: semaglutide reduced MACE by 20% (HR 0.80, 95% CI 0.72–0.90, p<0.001); absolute risk reduction: 1.5 percentage points (6.5% semaglutide vs 8.0% placebo); NNT: 67 patients treated for 3.3 years to prevent one MACE event; the weight loss achieved in SELECT: mean −9.4% body weight in semaglutide arm; the critical statistical analysis: when researchers statistically adjusted for the weight loss difference between arms, the MACE reduction remained significant — suggesting cardiovascular benefit is not fully explained by weight loss alone; additional SELECT findings: HsCRP (high-sensitivity CRP, a marker of systemic inflammation) reduced significantly in the semaglutide arm — consistent with direct anti-inflammatory mechanism; renal outcomes: SELECT also showed reduced kidney disease progression (a finding later extended by the dedicated FLOW trial)
LEADER 2016
the trial that started it — LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results): Marso et al. 2016, NEJM; N=9,340 type 2 diabetic patients with high cardiovascular risk; liraglutide 1.8mg/day (Victoza) vs placebo; follow-up: 3.8 years; result: −13% MACE (HR 0.87, 95% CI 0.78–0.97, p=0.01); cardiovascular death specifically: −22% (HR 0.78); this was the first GLP-1 trial to report cardiovascular benefit (vs the ELIXA exenatide trial in the same year which was neutral); the LEADER result shocked the cardiovascular community — the expected result was safety non-inferiority, not superiority; SUSTAIN-6: Marso et al. 2016 (companion paper in NEJM same issue): N=3,297 T2D patients; semaglutide 0.5mg or 1mg (Ozempic doses) vs placebo; follow-up: 2.1 years; result: −26% MACE (HR 0.74, 95% CI 0.58–0.95, p=0.02); particularly driven by −39% reduction in non-fatal stroke; the GLP-1 cardiovascular class effect: REWIND (dulaglutide): −12% MACE; PIONEER-6 (oral semaglutide 14mg): −21% MACE; EXSCEL (exenatide): neutral (HR 0.91, non-significant); the pattern: liraglutide, semaglutide, and dulaglutide show significant benefit; older/shorter-acting agents (exenatide) appear neutral — suggesting the continuous receptor engagement of long-acting GLP-1 RAs may be important for the cardiovascular mechanism
GLP-1R
receptors in heart — GLP-1 receptors (GLP-1R) are expressed in cardiac tissue, vascular endothelium, and smooth muscle cells — providing a direct pathway for GLP-1 cardioprotection independent of systemic metabolic effects; in the myocardium: GLP-1R activation → cAMP (cyclic AMP) increase → PKA (protein kinase A) activation → multiple cardioprotective effects: reduced cardiomyocyte apoptosis (programmed death) during ischemia; enhanced calcium handling → improved cardiac contractility; reduced oxidative stress in cardiomyocytes; activation of KATP channels → ischemic preconditioning mechanism (the same pathway activated by ischemic preconditioning, where brief periods of ischemia protect against subsequent prolonged ischemia); in the endothelium: GLP-1R activation → increased nitric oxide (NO) production → vasodilation + reduced endothelial inflammation; reduced ICAM-1 and VCAM-1 expression → less immune cell adhesion to vessel walls → reduced atherosclerotic plaque inflammation; in macrophages (within plaque): GLP-1R on macrophages → reduced NF-κB activation → reduced inflammatory cytokine secretion → less plaque inflammation; in the sinoatrial node: GLP-1R activation → modest increase in heart rate (the HR increase seen clinically with GLP-1 drugs is ~2–4 bpm) — a direct node effect; the sum of these direct cardiac and vascular effects provides a mechanistic explanation for why SELECT's MACE reduction persists after statistical adjustment for weight loss: weight loss is not the only mechanism
STEP-HFpEF
heart failure with preserved ejection fraction — an emerging major application; HFpEF (heart failure with preserved ejection fraction) is a heart failure syndrome in which the heart contracts normally but is stiff — it cannot fill properly; it is strongly associated with obesity and is now recognized as partially an obesity-driven inflammatory cardiomyopathy; existing heart failure medications (ARNIs, SGLT2i, spironolactone) work poorly in HFpEF; Kosiborod et al. 2023 (STEP-HFpEF, NEJM): N=529 obese HFpEF patients (BMI ≥30, no T2D); semaglutide 2.4mg vs placebo; follow-up: 52 weeks; co-primary endpoints: Kansas City Cardiomyopathy Questionnaire score (KCCQ, patient-reported HF symptoms) + 6-minute walk distance; results: semaglutide produced significant improvement in both KCCQ score (+7.8 points more than placebo, clinically meaningful) and 6-minute walk distance (+20m more than placebo); also significant: weight loss (−13.3% vs −2.6%), reduced CRP (anti-inflammatory marker), improved peak VO2; the STEP-HFpEF DM trial (patients with both HFpEF and T2D): confirmed similar benefits; GLP-1 drugs are now the most effective pharmacological intervention for HFpEF in obese patients — a population with no previously effective drug therapy; 2024 guidelines update: several major cardiology societies have incorporated GLP-1 RAs into HFpEF management recommendations in obese patients
GLP-1 Cardiovascular Outcomes Trials: Complete Summary
| Trial | Drug | Population | N | MACE Reduction | Key Secondary Findings |
|---|
| SELECT (2023) | Semaglutide 2.4mg | Obese, NO diabetes, established CV disease | 17,604 | −20% ✅ (p<0.001) | −24% kidney events; reduced CRP |
| LEADER (2016) | Liraglutide 1.8mg | T2D, high CV risk | 9,340 | −13% ✅ (p=0.01) | −22% CV death; −15% kidney events |
| SUSTAIN-6 (2016) | Semaglutide 0.5/1mg | T2D, high CV risk | 3,297 | −26% ✅ (p=0.02) | −39% non-fatal stroke |
| REWIND (2019) | Dulaglutide 1.5mg | T2D, mixed CV risk | 9,901 | −12% ✅ (p=0.026) | First to show benefit in primary prevention T2D |
| PIONEER-6 (2019) | Oral semaglutide 14mg | T2D, high CV risk | 3,183 | −21% (p=0.17, non-inferior) | Trending benefit; underpowered for superiority |
| EXSCEL (2017) | Exenatide QW | T2D, mixed CV risk | 14,752 | −9% (HR 0.91, non-significant) | Neutral; short-acting GLP-1 receptor kinetics may explain |
| STEP-HFpEF (2023) | Semaglutide 2.4mg | Obese HFpEF, NO diabetes | 529 | N/A (not MACE trial) | +7.8pt KCCQ; +20m walk distance; −CRP |
Implications for GLP-1 Users With Cardiovascular Risk
Who should specifically know about SELECT: any obese or overweight patient with a history of heart attack, stroke, coronary artery disease, peripheral artery disease, or established atherosclerosis; in these patients, semaglutide (Wegovy dose, 2.4mg/week) now has Level A evidence for cardiovascular risk reduction — the same category as statins and aspirin; this changes the conversation from "weight loss drug" to "cardiovascular disease drug that also reduces weight"; in the US, this has influenced insurance coverage: many payers who declined Wegovy for obesity are now approving it under cardiovascular indications following SELECT; the SELECT NNT of 67 over 3.3 years is competitive with established cardiovascular preventive therapies.
The inflammation angle — hsCRP as a biomarker: the SELECT trial showed semaglutide reduced hsCRP (high-sensitivity C-reactive protein) by approximately 37–40% — a larger anti-inflammatory effect than would be predicted by weight loss alone; hsCRP is one of the most validated cardiovascular risk biomarkers; CRP reduction of this magnitude is comparable to statin therapy; this suggests that monitoring hsCRP at baseline and at 3 months on GLP-1 therapy could help quantify the cardiovascular benefit in individual patients; patients with elevated baseline hsCRP (>2 mg/L) may derive proportionally greater benefit from the anti-inflammatory mechanism.
Complementary monitoring while on GLP-1 for CV risk: lipid panel every 6 months (GLP-1 reduces triglycerides significantly; modest LDL reduction); blood pressure (GLP-1 reduces systolic BP ~3–5 mmHg, additive to antihypertensives); hsCRP (anti-inflammatory monitoring); eGFR and urine ACR (kidney protection, especially relevant given FLOW trial data); the cardiovascular benefit of GLP-1 drugs is now considered a class effect for the long-acting agents — meaning patients should not switch to older short-acting agents (exenatide twice-daily) if cardiovascular risk reduction is a clinical goal.
CGM Monitoring →
Omega-3 EPA/DHA →